导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.38% | 2068/4773 |
| 近一周 | -1.87% | 3043/5465 |
| 近一月 | -3.35% | 2414/5421 |
| 近一季 | -5.84% | 2194/5231 |
| 近半年 | -0.03% | 1397/4920 |
| 近一年 | 5.44% | 1713/4394 |
| 近两年 | 55.02% | 1365/2954 |
| 近三年 | 35.52% | 895/2253 |
| 成立以来 | 63.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.28% 3109/4961 |
14.11% 1869/5312 |
- - |
- - |
| 2025 | 22.86% 1932/4813 |
-0.96% 2489/3635 |
2.61% 1466/4076 |
19.46% 2144/4524 |
1.20% 1477/4813 |
| 2024 | 17.25% 710/3463 |
2.93% 664/2808 |
-1.22% 990/3014 |
17.47% 1184/3129 |
-1.83% 1851/3463 |
| 2023 | -8.80% 1058/2656 |
4.62% 906/2280 |
-3.76% 889/2385 |
-2.87% 775/2515 |
-6.73% 1898/2655 |
| 2022 | -19.08% 801/2207 |
-14.20% 914/1919 |
7.16% 519/2016 |
-13.67% 945/2113 |
1.95% 1080/2208 |
| 2021 | 6.08% 527/1822 |
-1.66% 527/1255 |
8.35% 630/1330 |
-2.85% 596/1466 |
2.47% 584/1822 |
| 2020 | 43.33% 248/1250 |
-7.63% 558/1028 |
15.86% 469/1067 |
16.38% 155/1164 |
15.08% 234/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.70% 787/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 方正富邦沪深300ETF VS. 长安沪深300非周期A(740101) |